On October 24, 2023 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium (Press release, Sangamo Therapeutics, OCT 24, 2023, View Source [SID1234636265]). Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from its neurology epigenetic regulation programs, and advancements in the CAR-Treg pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data we are presenting at ESGCT reflect the important advances being made across our neurology and CAR-Treg pipelines," said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo. "We are excited to showcase these innovations, which reinforce the potential of our science to create transformative treatments for patients suffering with serious diseases."

Data to be presented at the ESGCT Annual Congress include an oral presentation demonstrating how zinc finger activators (ZF-As) may be designed to potentially address neurodevelopmental disorders such as autism spectrum disorder and intellectual disability, for which limited therapeutic treatments currently exist. This presentation will show how ZF-As can be designed to restore normal gene and protein expression of SCN2A in vitro and in vivo. This will be accompanied by a poster presentation demonstrating Shank3 gene activation, mediated by ZF-As as a potential therapeutic approach for Phelan-McDermid syndrome. Both datasets originate from pre-clinical programs previously co-developed in partnership with Novartis.

Additional presentations at the ESGCT Annual Congress will unveil for the first time pre-clinical data showing that autologous MOG-CAR-Tregs may provide a long-lasting treatment option to potentially address the underlying cause of multiple sclerosis, as well as updated pre-clinical data evaluating IL23R-CAR-Tregs as a potentially effective treatment option to address inflammation for patients with Crohn’s disease. Data will also showcase our platform capability of efficient and durable epigenetic cell engineering using compact ZF-Repressors to target immune checkpoints with the potential to improve the anti-tumor activity of T cells in cancer therapy.

ESGCT Annual Congress Presentations and Invited Sessions

Epigenetic Regulation for Neurology:

Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency
Abstract No. OR09
Oral Presentation – October 24; 17:00-19:00
Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
Abstract No. P415
Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30
Cell Therapy
Regulatory T-Cells (CAR-Tregs)

Myelin Oligodendrocyte Glycoprotein (MOG)-CAR-Tregs – A novel approach to treat multiple sclerosis
Abstract No. P475
Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30
Evaluation of IL23R as a target for CAR-Tregs at the site of inflammation in subjects with Crohn’s Disease
Abstract No. P487
Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30
Multimerization of Chimeric Antigen Receptor (CAR) binding domains: A solution to assess tissue specificity of low to medium affinity scFv
Abstract No. P503
Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30
CAR-T in Oncology

Multiplex targeting of immune checkpoints with compact zinc finger repressors to improve anti-tumor activity of T cells
Abstract No. P212
Poster Presentation – October 25; 18:15 to 19:30 and October 26; 19:30 to 20:30
All ESGCT presentations are available on the Sangamo website.